Neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction — comparison of postoperative mortality and complications, toxicity, and pathological tumor response

PURPOSE: In 2012, the CROSS trial implemented a new neoadjuvant radiochemotherapy protocol for patients with locally advanced, resectable cancer of the esophagus prior to scheduled surgery. There are only limited studies comparing the CROSS protocol with a PF-based (cisplatin/5-fluorouracil) nRCT pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenz, Eric, Weitz, Anna, Reinstaller, Therese, Hass, Peter, Croner, Roland S., Benedix, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630244/
https://www.ncbi.nlm.nih.gov/pubmed/37935904
http://dx.doi.org/10.1007/s00423-023-03091-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630244/
https://www.ncbi.nlm.nih.gov/pubmed/37935904
http://dx.doi.org/10.1007/s00423-023-03091-0

Ejemplares similares